PsilodexMedication × psilocybin
Your list , 0 items
Medication class

SSRI antidepressants and psilocybin.

7 records in this group. 6 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

7Records
6With human data

Overview

Reviewed 2026-10-25

SSRIs are the medication class most studied with psilocybin. In an online survey, reports from people taking SSRIs often described psilocybin's effects as weaker than expected, including some reports after the SSRI had been stopped (Gukasyan 2023); Reddit posts show the same pattern (Sakai 2024). With LSD, 28 of 32 people who had taken an SSRI or trazodone for more than 3 weeks reported a reduced or absent response in a retrospective questionnaire (Bonson 1996).

In a randomized crossover study, 23 healthy adults took escitalopram for 14 days before psilocybin 25 mg. Compared with placebo pretreatment, positive mood effects were unchanged, and anxiety and rises in blood pressure were smaller; the authors note that longer pretreatment and studies in patients are still needed (Becker 2022). In an open-label trial without a comparison group, 19 people with treatment-resistant depression took psilocybin 25 mg while continuing an SSRI, with no serious adverse events (Goodwin 2023).

One systematic review describes serotonin toxicity from psilocybin as unlikely, because psilocybin causes little serotonin release (Sarparast 2022); another found no serious adverse events with antidepressants apart from a few case reports (Halman 2024). Unlikely is not the same as impossible: the published data are small, and rare reactions may not yet have been seen.

Stopping an antidepressant, especially suddenly, can cause withdrawal (discontinuation) symptoms or a return of depression (Zoloft prescribing information). Most clinical trials required stopping SSRIs before enrollment (Tap 2025), and later analyses of trial data differ on whether stopping changes the response to psilocybin (Erritzoe 2024; Marwood 2024).

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Sources for this overview
  1. Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
  2. Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630.
  3. Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
  4. Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
  5. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
  6. Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
  7. Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
  8. Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
  9. Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
  10. Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
  11. Zoloft (sertraline) prescribing information, sections 2 and 14 (DailyMed)

Also searched as SSRI · SSRIs · selective serotonin reuptake inhibitor

01 What the evidence covers

Best evidence available per medication
1Controlled trial
5Open-label trial
1No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Citalopram · CelexaEvidence: Open-label trial

    Depression (major depressive disorder)

    SSRIs often weakened psilocybin's effects in real-world reports; one trial found effects largely kept. Serotonin syndrome is unlikely, not impossible. Stopping suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Escitalopram · LexaproEvidence: Controlled trial

    Depression (major depressive disorder); Generalized anxiety disorder

    In one controlled study, escitalopram kept psilocybin's positive mood effects and reduced anxiety and blood pressure rises. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Fluoxetine · Prozac, SarafemEvidence: Open-label trial

    Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)

    Antidepressants like this often made psilocybin feel weaker in real-world reports, and fluoxetine lingers for weeks. Stopping it suddenly after regular use can cause relapse.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Fluvoxamine · LuvoxEvidence: No psilocybin data

    Obsessive-compulsive disorder (OCD)

    SSRIs often made psilocybin feel weaker in real-world reports; fluvoxamine may also slow how the body clears psilocybin.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Paroxetine · Paxil, Pexeva, BrisdelleEvidence: Open-label trial

    Depression; Obsessive-compulsive disorder (OCD)

    SSRIs like paroxetine often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Sertraline · ZoloftEvidence: Open-label trial

    Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)

    SSRIs like sertraline often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Vilazodone · ViibrydEvidence: Open-label trial

    Major depressive disorder (adults)

    It acts on serotonin and may make psilocybin feel weaker, as SSRIs do. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
7Dehydration or electrolyte risk
7Lowers seizure threshold or carries seizure risk
7Psychiatric reactions
7Serotonergic
7Withdrawal or rebound if stopped abruptly
5QT-prolonging
1Anticholinergic
1Liver injury

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. Every medication in this group is psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
7Chisamore N, Kaczmarek ES, Doyle Z, et al. Comparing antidepressant effects of psilocybin-assisted psychotherapy in individuals unmedicated at screening versus individuals discontinuing medications. Can J Psychiatry 2025;70(10):759–767.
7Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
7Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
7Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
7Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
7Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
6Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630.
6Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
3Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
2Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903.
1Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
1Becker AM, Humbert-Droz M, Mueller L, et al. Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial. Clin Pharmacol Ther 2025;117(6):1784–1792.
1Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.

Related classes

Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25